Exelixis, Inc..
EXEL.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Exelixis, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to treat cancer. The company's primary focus is on developing targeted therapies for various types of cancers. Their key products include CABOMETYX (cabozantinib), a tyrosine kinase in...Show More
Better Health for All
-30
Exelixis' core mission is to develop and commercialize cancer treatments, aiming to help patients recover stronger and live longer, with 100% of its portfolio dedicated to this purpose.
1
The company has no revenue from products with significant negative health impacts. Exelixis offers a patient assistance program providing free medication, a co-pay program for commercially insured patients (as little as $0/month), a 15-day free trial, and a dose exchange program.
2
However, the co-pay program is not available to patients with government-funded insurance, and eligibility restrictions apply to other programs.
3
The company states it ensures no patient will go without medicine due to inability to pay, and is dedicated to increasing representation of underrepresented populations in clinical trials.
4
Exelixis discloses drug prices in Vermont and provides comprehensive risk disclosures for investigational medicines.
5
The company invests in advancing scientific discourse and improving patient care through grants and programs, and integrates ESG considerations into R&D.
6
Exelixis supports independent patient assistance foundations and non-profit organizations.
7
The company provides contact information for healthcare professionals and has a Corporate Code of Conduct and Ethics Helpline.
8
Exelixis defends its intellectual property rights, having successfully litigated to prevent a generic cabozantinib product from launching before January 15, 2030.
9
Fair Money & Economic Opportunity
0
Exelixis, Inc. is a biopharmaceutical company focused on developing and commercializing cancer medicines. Its core business does not involve lending, insuring, moving, or storing money for consumers, nor does it offer consumer credit products. Therefore, the KPIs related to financial services, such as APRs, loan books, debt ratios, open banking APIs, and financial literacy programs, are not applicable to the company's operations as defined by the rubric. While Exelixis provides patient assistance programs (EASE Co-Pay Program, EASE Patient Assistance Program) that offer free medication or $0 co-pay for eligible patients, and supports over 1,200 nonprofit organizations through employee giving and volunteer programs, these initiatives do not align with the specific quantitative thresholds or definitions of the financial services-focused KPIs in the rubric, which are designed for financial institutions.
1
Fair Pay & Worker Respect
20
Exelixis reported a CEO-to-median worker pay ratio of 40:1 in 2024.
1
The company's Total Recordable Incident Rate (TRIR) was 0.799 for January to June 2024, following a TRIR of 0.4 in 2023 and 1.14 in 2022.
2
Exelixis states it has a 1:1 gender pay parity ratio, with no gender or ethnicity-based disparities found in its most recent annual analysis.
3
However, employee engagement is low, with an overall employee rating of 42/100 and a Glassdoor rating of 2.1 out of 5 stars.
4
Employee turnover has remained consistently below average for the U.S. life sciences industry over the past five fiscal years.
5
The company is facing a wrongful termination lawsuit filed in August 2024, alleging violations of the Fair Employment and Housing Act and Title VII of the Civil Rights Act.
6
Exelixis offers 100% employer-funded health insurance coverage, including for dependents and mental health services.
7
The company laid off 175 staffers in January 2024 and an additional 130 employees in August 2025, including four vice presidents and several scientists, and is shutting down its Pennsylvania site.
8
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence was found across the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. While general commitments to ethical behavior, compliance programs, and supplier evaluation are mentioned, there is no data on fair-trade certification, audit frequency, forced or child labor incidents, supply chain traceability percentages for suppliers, remediation speed, ethical clause coverage in supplier contracts, high-risk materials spend, or supplier diversity spend.
1
Product serialization for tracking, as mentioned, does not provide a percentage of supplier traceability.
2
Honest & Fair Business
-10
Exelixis provides a confidential and anonymous Ethics Helpline, accessible 24/7 and operated by a third-party, with anti-retaliation policies for reporting potential violations.
1
However, there is no explicit evidence regarding independent investigation processes or the effectiveness of the policy. The company's board of directors demonstrates high independence, with 91% of its members being independent.
2
Exelixis has anti-corruption policies and procedures, including a Code of Conduct and Ethics Policy and a Policy on Interactions with Healthcare Professionals, which sets a cumulative annual spending limit of $2,500 per healthcare professional for non-prohibited promotional items and activities.
3
These policies are designed to comply with California SB 1765 and U.S. Department of Health and Human Services OIG Guidance, but the frequency of training and effectiveness metrics are not specified.
4
Kind to Animals
-60
Exelixis conducts preclinical trials of its drugs on animals, including mice, Drosophila, C. elegans, and zebrafish, for drug testing and clinical trials, such as evaluating drug candidates in animal models of atherosclerosis.
1
There is no explicit mention of a formal animal testing policy, nor any indication of restrictions on non-essential testing or a commitment to reduction.
2
The company reinvested 57% of its total revenues in R&D in fiscal year 2023, but there is no specific percentage allocated to developing animal-free technologies or alternatives.
3
No War, No Weapons
0
Exelixis, Inc. is a biopharmaceutical company focused on developing and commercializing cancer treatments.
1
The company's core business activities do not involve arms manufacturing, military contracts, or conflict facilitation.
2
Its technology is focused on cancer treatment and is not considered dual-use.
3
There is no evidence of revenue from arms or defense contracts, sales to embargoed regimes, or lobbying on arms control.
4
The board's oversight is related to general business and financial risks, not defense-related activities.
5
The company has no stated ethical red lines related to weapons, nor is there any evidence of exposure to controversial weapons, investment in peace technology, or procurement from conflict zones.
6
Planet-Friendly Business
-40
In 2023, Exelixis sourced 10.65% of its gross electricity usage from solar generation, with 634,200 kWh generated from solar out of a total gross usage of 5,952,420 kWh.
1
The company reported no specific regulatory actions, violations, fines, or compliance issues in its 2023 Corporate Values & Sustainability Report Summary.
2
Respect for Cultures & Communities
0
No evidence available to assess Exelixis, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
10
The company has no documented data breaches and states that cybersecurity threats have not materially affected operations.
1
All employees receive cybersecurity training upon hire with annual or more frequent training, and annual healthcare compliance training is required for relevant personnel.
2
The company proactively identifies vulnerabilities in its systems with threat intelligence.
3
Its website is designed to honor Global Privacy Control signals.
4
Exelixis retains personal information only as long as necessary for specified purposes or legal requirements.
5
The company complies with various regulations including California SB 1765, OIG Guidance, PhRMA Code, CCPA (including CPRA effective January 1, 2023), GDPR, HIPAA, and the Drug Supply Chain Security Act.
6
Users have comprehensive control options, including the right to request disclosures, access, rectification, or erasure of personal information, restrict processing, opt-out of data sharing for advertising, obtain data in portable format, and limit sensitive personal information use.
7
These rights can be exercised via email, phone, or web form, and include an appeal process.
8
Zero Waste & Sustainable Products
-40
Exelixis has implemented waste reduction initiatives, including diverting 2,720 lbs of glassware, cardboard, and foam from July 2022 to June 2023.
1
During the same period, the company reduced flammable/hazardous solvents by approximately 800 liters.
2
For the twelve months ended June 30, 2024, Exelixis generated 52,995 lbs of hazardous waste and 44,488 lbs of medical waste.
3
The company has not reported any waste disposal violations or enforcement actions in its Corporate Values & Sustainability Reports covering 2021 through June 2024.
4